Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Edward J. Bastyr"'
Autor:
A. N. Higdon, Shuyu Zhang, Juliana M. Bue-Valleskey, Scott J. Jacober, Edward J. Bastyr, Arun J. Sanyal, Axel Haupt, Annette M. Chang, Mark L. Hartman, Byron J. Hoogwerf, Kenneth Cusi
Publikováno v:
Diabetes, Obesity and Metabolism. 18:50-58
AIMS To compare effects of basal insulin peglispro (BIL), a hepatopreferential insulin, to insulin glargine (glargine) on aminotransferases and liver fat content (LFC) in patients with type 1 and type 2 diabetes (T1D, T2D). MATERIALS AND METHODS Data
Autor:
Melvin J. Prince, Annette M. Chang, Yongming Qu, Shuyu Zhang, Julio Rosenstock, Edward J. Bastyr, Michel Marre
Publikováno v:
Diabetes, Obesity & Metabolism
Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action, resulting from reduced peripheral effects. This report summarizes hypoglycaemia data from five BIL phase III studies with insulin glargine as the comparator, incl
Autor:
Kenneth Cusi, Byron J. Hoogwerf, Edward J. Bastyr, Annette M. Chang, Qianyi Zhang, Shuyu Zhang, Robert J. Konrad, Juliana M. Bue-Valleskey, Scott J. Jacober, Arun J. Sanyal, Axel Haupt, Mark L. Hartman
Publikováno v:
Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 66(3)
Data on cytokeratin-18 (K-18) and enhanced liver fibrosis (ELF) score in insulin-treated diabetes patients with non-alcoholic fatty liver disease (NAFLD) are limited. This study analyzed phase III data comparing basal insulin peglispro (BIL) and insu
Autor:
Edward J. Bastyr, Wendra M. Foster, Sreekumar G. Pillai, Axel Haupt, M Farmen, Byron J. Hoogwerf, C Harris, Suman Duvvuru, Sudha S. Shankar, Pallav Bhatnagar
Publikováno v:
The pharmacogenomics journal. 18(3)
Basal insulin peglispro (BIL) is a novel insulin with hepato-preferential action. In phase 3 trials, BIL showed significantly improved glycemic control but higher levels of transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase
Autor:
Louis Vignati, Matthias H. Tschöp, Rune Haubo Bojesen Christensen, Richard D. DiMarchi, Edward J. Bastyr, Klara Owen, Christophe Schmitt, Juan Pablo Frias
Publikováno v:
Cell Metab. 26, 343-352.e2 (2017)
Unimolecular dual incretins derived from hybridized glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) sequences have demonstrated synergistic reduction of adiposity in animal models and reductions of hyperglycemia in
Autor:
Nazila Shahri, Katherine R. Tuttle, Janet B. McGill, Edward J. Bastyr, Pamela W. Anderson, Keri Kles Poi
Publikováno v:
American Journal of Kidney Diseases. 65:634-636
Autor:
Byron J. Hoogwerf, Bertrand Cariou, Trevor J. Orchard, Henry N. Ginsberg, Edward J. Bastyr, Scott J. Jacober, Annette M. Chang, Junxiang Luo, Tibor Ivanyi, Lei Chen, Juliana M. Bue-Valleskey
Publikováno v:
Diabetes, obesitymetabolism. 18(11)
Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action resulting from reduced peripheral effects. This report provides an integrated summary of lipid changes at 26 weeks with BIL and comparator insulins (glargine, NPH)
Autor:
Jiani Mou, Edward Franek, Caryl J. Antalis, Florence Travert, Yongming Qu, Scott J. Jacober, Mark L. Hartman, Myriam Rosilio, Helen Lunt, Edward J. Bastyr, Richard M. Bergenstal
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To evaluate the efficacy and safety of basal insulin peglispro (BIL) with those of insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (T2D). Methods In this phase III, multicentre, double-blind,
Autor:
Edward J. Bastyr, T. Blevins, Guillermo E. Umpierrez, Julio Rosenstock, James H. Anderson, C. Cheng
Publikováno v:
Diabetes, Obesity and Metabolism. 13:418-425
Aim: To evaluate the efficacy and tolerability of once-weekly LY2189265 (LY), a novel glucagon-like peptide-1 (GLP-1) IgG4-Fc fusion protein, in patients with type 2 diabetes failing oral antihyperglycaemic medications (OAMs). Methods: Placebo-contro